March 17, 2005 -- Biotech shrugged off rising oil prices and mounted a rally of its own on Thursday, with the Centient Biotech 200 rising 6.22 points to end at 3190.59, a .20% climb. Biogen Idec continued to regain its footing, with reassuring words about Avonex and Tysabri, Amylin won FDA approval for its diabetes drug, GTC Biotherapeutics must do more tests before European authorities will approve ATryn, aaiPharma and Ligand Pharma both got hit when they missed deadlines for filing annual reports, Targacept formally withdraw its IPO application, while CombinatoRx is on a “Day-to-Day” schedule. More details...
